Sonntag, Juli 31, 2022
StartBiotechnologyBavarian Nordic - Transactions in Reference to Share Purchase-Again Program and Termination...

Bavarian Nordic – Transactions in Reference to Share Purchase-Again Program and Termination of Share Purchase-Again Program – Bio Tech Winners


Final Up to date on Might 18, 2022 by GlobeNewsWire

COPENHAGEN, Denmark, Might 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) publicizes that the share buy-back program, which was introduced and initiated on Might 9, 2022, has now been terminated, because the supposed variety of shares beneath this system has been repurchased. This system was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which collectively represent the Protected Harbour Regulation. The aim of this system was to satisfy the Firm’s obligations arising from the share-based incentive program for the Board of Administrators and Govt Administration.

Below this system Bavarian Nordic A/S has purchased again 71,562 shares, cf. the desk beneath:

Transaction dateVariety of sharesCommon buy worth, DKKTransaction Worth, DKKMight 9, 202215,000125.631,884,450May 10, 202213,000126.271,641,510May 11, 202210,000131.341,313,400May 12, 20229,300126.771,178,961May 16, 20227,000130.64914,480May 17, 20226,000134.39806,340May 18, 202211,262140.671,584,226Gathered beneath this system71,562130.289,323,367

The small print for every transaction made beneath the share repurchase program have been hooked up to this announcement.

With the transactions said above, Bavarian Nordic A/S owns a complete of 146,330 personal shares, comparable to 0.21% of the share capital. The entire quantity of shares within the firm is 70,472,935 together with treasury shares.

About Bavarian Nordic
Bavarian Nordic is a completely built-in vaccines firm centered on the event, manufacturing and commercialization of life-saving vaccines. We’re a world chief in smallpox vaccines and have been a long-term provider to the U.S. Authorities of a non-replicating smallpox vaccine, which has been authorized by the FDA, additionally for the safety in opposition to monkeypox. The vaccine is authorized as a smallpox vaccine in Europe and Canada. Our business product portfolio moreover incorporates market-leading vaccines in opposition to rabies and tick-borne encephalitis. Utilizing our stay virus vaccine platform know-how, MVA-BN(R), we have now created a various portfolio of proprietary and partnered product candidates designed to save lots of and enhance lives by unlocking the facility of the immune system, together with an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Firms of Johnson & Johnson. We’re additionally dedicated to the event of a subsequent technology COVID-19 vaccine. For extra info go to www.bavarian-nordic.com.

Ahead-looking statements
This announcement contains forward-looking statements that contain dangers, uncertainties and different elements, a lot of that are exterior of our management, that would trigger precise outcomes to vary materially from the outcomes mentioned within the forward-looking statements. Ahead-looking statements embrace statements regarding our plans, goals, objectives, future occasions, efficiency and/or different info that isn’t historic info. All such forward-looking statements are expressly certified by these cautionary statements and some other cautionary statements which can accompany the forward-looking statements. We undertake no obligation to publicly replace or revise forward-looking statements to mirror subsequent occasions or circumstances after the date made, besides as required by regulation.

Contacts
Europe: Rolf Sass S?rensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Firm Announcement no. 18 / 2022

Attachment

2022-18-en

RELATED ARTICLES

Most Popular

Recent Comments